Canaccord raised the firm’s price target on Guardant Health (GH) to $125 from $100 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. Among their covered companies, they maintain the highest level of conviction in the risk-reward profile and share price appreciation potential for Guardant Health.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $120 from $100 at Mizuho
- Guardant Health price target raised to $120 from $100 at BofA
- Guardant Health price target raised to $155 from $115 at Leerink
- Guardant Health: Strong Growth Potential and Market Positioning Justify Buy Rating
- Guardant Health price target raised to $120 from $90 at JPMorgan